On track to report interim data in six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC in 4Q 2024Expect…
BRISBANE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted…
SOLANA BEACH, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on…
Ewing Sarcoma is a Highly Metastatic Form of Sarcoma and the Second Most Prevalent Primary Malignant Tumor in Children and…
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, Inc., (“Rectify”) a biotechnology company developing positive functional modulators (PFMs),…
- Late-Breaking Abstract on Results of Phase 3 BOND-003 Trial of Cretostimogene Monotherapy in BCG-Unresponsive NMIBC Accepted at the Society…
Platform developed in collaboration with CRScube, capitalizing on learnings from world-leading pharma and biotech companies NOTTINGHAM, England, Nov. 11, 2024 /PRNewswire/…
HAYWARD, Calif., Nov. 11, 2024 /PRNewswire/ -- Avirmax's Chief Executive and Scientific Officer, Dr. Shengjiang Shawn Liu, Ph.D., will chair the…
- Published clinical study on sleep apnea patients in the prestigious journal Digital Health - Clinical research on HoneyNaps SOMNUM…
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients…